Posted by Michael Wonder on 28 Nov 2022
NICE recommends Rinvoq (upadacitinib) as treatment option for moderately to severely active ulcerative colitis in adults
25 November 2022 - Publication of positive Final Draft Guidance from NICE is supported by data from three clinical studies that demonstrated participants receiving upadacitinib had the ability to achieve clinical remission at week 8 and longer term at week 52 (p<0.0001 vs placebo in all studies).
AbbVie today announced that NICE has issued positive Final Draft Guidance recommending Rinvoq (upadacitinib) within its marketing authorisation as an option for moderately to severely active ulcerative colitis in adults when conventional or biologic treatment cannot be tolerated or the condition has not responded well enough or has stopped responding to these treatments.
